论文部分内容阅读
目前胃癌是全球高发恶性肿瘤的第4位,病死率位于恶性肿瘤的第2位,严重威胁人类的健康。胃癌的转移和复发是影响预后的主要因素[1],而胃癌细胞在胃周淋巴结、腹腔以及外周血中的微转移可能是导致转移和复发的主要原因。近些年来,随着免疫组织化学和反转录-聚合酶链反应在临床上的应用,使胃癌淋巴结微转移的检测成为可能。目前根治性手术可以有效的预防胃癌淋巴结复发率[2],随着化疗进展的提高,包括新的抗癌药物应用,使得早期胃癌5年生存率为90%,进展期胃癌5年生存率<40%。但是如何进行胃癌淋巴结微转移检测,减少复发率、提高生存率仍是我们目前面临的难题。
Currently, gastric cancer ranks the fourth in the world with high incidence of malignant tumors and its case fatality rate ranks second in malignant tumors, which seriously threatens human health. Metastasis and recurrence of gastric cancer are the main factors affecting the prognosis [1], while micrometastasis of gastric cancer cells in the peritumoral lymph nodes, peritoneal cavity and peripheral blood may be the main reason leading to metastasis and recurrence. In recent years, with the clinical application of immunohistochemistry and reverse transcription - polymerase chain reaction, the detection of lymph node micrometastasis in gastric cancer has become possible. The current radical surgery can effectively prevent the recurrence rate of gastric cancer lymph nodes [2], with the progress of chemotherapy, including the application of new anti-cancer drugs, making 5-year early gastric cancer survival rate was 90%, 5-year advanced gastric cancer survival rate < 40%. However, how to carry out micrometastasis detection of gastric cancer, reduce the recurrence rate and improve the survival rate is still the problem we are facing.